PROFOUND MEDICAL CORP (PRN.CA) Stock Price, Forecast & Analysis
TSX:PRN • CA74319B5027
PRN.CA Key Statistics, Chart & Performance
The current stock price of PRN.CA is 9.53 CAD. In the past month the price decreased by -19.91%. In the past year, price decreased by -13.87%.
PRN.CA Technical Analysis
PRN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PRN.CA. While PRN.CA has a great health rating, there are worries on its profitability.
PRN.CA Financial Highlights
Over the last trailing twelve months PRN.CA reported a non-GAAP Earnings per Share(EPS) of -1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93% | ||
| ROE | -122.4% | ||
| Debt/Equity | 0 |
PRN.CA Forecast & Estimates
5 analysts have analysed PRN.CA and the average price target is 15.56 CAD. This implies a price increase of 63.22% is expected in the next year compared to the current price of 9.53.
For the next year, analysts expect an EPS growth of -32.56% and a revenue growth 55.62% for PRN.CA
PRN.CA Ownership
PRN.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TLT | THERALASE TECHNOLOGIES INC | N/A | 75.833M | ||
| MIR | MEDMIRA INC | N/A | 53.082M | ||
| CNVI | CONAVI MEDICAL CORP | N/A | 43.436M | ||
| PINK | PERIMETER MEDICAL IMAGING AI | N/A | 36.714M | ||
| ASG | AURORA SPINE CORP | N/A | 23.552M | ||
| VPT | VENTRIPOINT DIAGNOSTICS LTD | N/A | 23.296M | ||
| NSCI | NANALYSIS SCIENTIFIC CORP | N/A | 21.46M | ||
| MDX | MEDX HEALTH CORP | N/A | 19.676M | ||
| THRM | THERMA BRIGHT INC | N/A | 3.409M |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find more ETFs on the Canadian exchanges | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find more growth stocks the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About PRN.CA
Company Profile
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Company Info
PROFOUND MEDICAL CORP
2400 Skymark Ave Unit 6
Mississauga ONTARIO L4W 5K5 CA
CEO: Arun Menawat
Employees: 142
Phone: 16474761350
PROFOUND MEDICAL CORP / PRN.CA FAQ
What does PROFOUND MEDICAL CORP do?
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
What is the stock price of PROFOUND MEDICAL CORP today?
The current stock price of PRN.CA is 9.53 CAD. The price increased by 7.08% in the last trading session.
Does PRN stock pay dividends?
PRN.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRN stock?
PRN.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the market cap for PROFOUND MEDICAL CORP?
PROFOUND MEDICAL CORP (PRN.CA) has a market capitalization of 345.84M CAD. This makes PRN.CA a Small Cap stock.
Can you provide the upcoming earnings date for PROFOUND MEDICAL CORP?
PROFOUND MEDICAL CORP (PRN.CA) will report earnings on 2026-03-05, after the market close.